

ASX Announcement

5 August 2025

2025 Annual General Meeting – Director Nominations

Cogstate (ASX:CGS) advises that the Annual General Meeting (AGM) of CGS is scheduled for Thursday, 16 October 2025.

Further to Listing Rule 3.13.1, Listing Rule 14.3 and Clause 47(e)(iii) of the Company's Constitution, nominations for election of directors at the AGM must be received not less than 45 Business Days before the meeting.

This announcement was authorised for release by Mr Brad O'Connor, Chief Executive Officer of Cogstate Ltd.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. In this market, Cogstate has partnered with pharmaceutical company, Eisai, to distribute Cogstate assessments in Asia. For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor, Chief Executive Officer, boconnor@cogstate.com